Although previous studies in vivo have suggested a tumour-related upregulation of IGFBP-3 levels, clinical studies have yet to determine IGFBP-3 epithelial protein expression in breast cancers; this is the first IHC study. This evidence concerns the gene IGFBP3 and neoplasm.